Antigenic variation in rabies and rabies-related viruses: cross-protection independent of glycoprotein-mediated virus-neutralizing antibody
- PMID: 3655404
- DOI: 10.1093/infdis/156.5.815
Antigenic variation in rabies and rabies-related viruses: cross-protection independent of glycoprotein-mediated virus-neutralizing antibody
Abstract
Immunization experiments with vaccines prepared from the PM and ERA strains of rabies virus demonstrated that in mice, only ERA vaccine primes for an anamnestic response to the rabies-related strain Duvenhage (DUV6); in rabbits, both ERA and PM vaccines induced immunologic memory to DUV6 virus. In mice, ERA vaccine, but not an equal concentration of PM vaccine, conferred protection against a lethal challenge infection with DUV6 virus. This result indicated that the protective activity correlated with the vaccine's ability to induce immunologic memory. A vaccine prepared from a sequentially selected, neutralization-resistant, multiple-variant virus conferred protection against challenge with the parental strain, a result indicating that antigenic variation of the glycoprotein may not be the sole factor in determining the relative efficacy of rabies prophylaxis. We found no correlation between titers of neutralizing antibody and mortality rates in mice immunized with purified glycoprotein from these viruses.
Similar articles
-
Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice.Vaccine. 1988 Aug;6(4):362-8. doi: 10.1016/0264-410x(88)90184-3. Vaccine. 1988. PMID: 2461007
-
Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein.J Gen Virol. 1989 Feb;70 ( Pt 2):291-8. doi: 10.1099/0022-1317-70-2-291. J Gen Virol. 1989. PMID: 2471786
-
Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.Proc Natl Acad Sci U S A. 1984 Nov;81(22):7194-8. doi: 10.1073/pnas.81.22.7194. Proc Natl Acad Sci U S A. 1984. PMID: 6095272 Free PMC article.
-
New approaches to the development of live attenuated rabies vaccines.Hybrid Hybridomics. 2002 Apr;21(2):129-34. doi: 10.1089/153685902317401735. Hybrid Hybridomics. 2002. PMID: 12031103 Review.
-
Rabies vaccine prepared in human cell cultures: progress and perspectives.Rev Infect Dis. 1980 May-Jun;2(3):433-48. doi: 10.1093/clinids/2.3.433. Rev Infect Dis. 1980. PMID: 6158081 Review.
Cited by
-
Evaluation of species identification and rabies virus characterization among bat rabies cases in the United States.J Am Vet Med Assoc. 2020 Jan 1;256(1):77-84. doi: 10.2460/javma.256.1.77. J Am Vet Med Assoc. 2020. PMID: 31841089 Free PMC article.
-
A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.J Virol. 2013 Feb;87(3):1618-30. doi: 10.1128/JVI.02470-12. Epub 2012 Nov 21. J Virol. 2013. PMID: 23175365 Free PMC article.
-
T and B cell human responses to European bat lyssavirus after post-exposure rabies vaccination.Clin Exp Immunol. 1991 Aug;85(2):224-30. doi: 10.1111/j.1365-2249.1991.tb05709.x. Clin Exp Immunol. 1991. PMID: 1864001 Free PMC article.
-
Cells with natural killer activity in human rabies.Clin Exp Immunol. 1992 Sep;89(3):414-8. doi: 10.1111/j.1365-2249.1992.tb06972.x. Clin Exp Immunol. 1992. PMID: 1381301 Free PMC article.
-
Expression of the rabies virus nucleoprotein in plants at high-levels and evaluation of immune responses in mice.Plant Cell Rep. 2008 Apr;27(4):677-85. doi: 10.1007/s00299-007-0324-9. Epub 2008 Feb 13. Plant Cell Rep. 2008. PMID: 18270708
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources